Page last updated: 2024-11-03

rabeprazole and Vomiting

rabeprazole has been researched along with Vomiting in 4 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.

Research Excerpts

ExcerptRelevanceReference
"Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)."9.17Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013)
": The efficacy and safety of rabeprazole, a proton pump inhibitor, were studied in infants with gastroesophageal reflux disease (GERD)."5.19Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. ( Hoffman, D; Hu, P; Hussain, S; Kierkus, J; Lekich, R; Sloan, S; Treem, W, 2014)
"The aim of the present study was to evaluate 24-week maintenance of efficacy and safety of rabeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD)."5.19Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. ( Haddad, I; Hu, P; Kierkus, J; Leitz, GJ; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2014)
"Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)."5.17Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013)
"Symptom eradication in patients with Barrett's esophagus (BE) does not guarantee control of acid or duodenogastroesophageal reflux (DGER)."1.42Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. ( Bhat, YM; Falk, GW; Maqbool, S; Richter, JE; Vaezi, MF; Yachimski, P, 2015)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haddad, I2
Kierkus, J3
Tron, E2
Ulmer, A2
Hu, P3
Sloan, S3
Silber, S2
Leitz, G1
Hussain, S1
Hoffman, D1
Lekich, R1
Treem, W1
Leitz, GJ1
Yachimski, P1
Maqbool, S1
Bhat, YM1
Richter, JE1
Falk, GW1
Vaezi, MF1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc[NCT00787891]Phase 3127 participants (Actual)Interventional2009-01-31Completed
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Dis[NCT00992589]Phase 3344 participants (Actual)Interventional2009-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg0.2
Rabeprazole Sodium 1.0 mg/kg0.2

The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)

The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-1.3
Rabeprazole Sodium 1.0 mg/kg-1.0

The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-2.9
Rabeprazole Sodium 1.0 mg/kg-1.4

The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)

The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12

InterventionScores on a scale (Mean)
Rabeprazole Sodium 0.5 mg/kg-11.5
Rabeprazole Sodium 1.0 mg/kg-8.5

The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks

InterventionPercentage of participants (Number)
Rabeprazole Sodium 0.5 mg/kg78
Rabeprazole Sodium 1.0 mg/kg83

The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)

Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks

InterventionPercentage of patients (Number)
Rabeprazole Sodium 0.5 mg/kg92
Rabeprazole Sodium 1.0 mg/kg88

Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)

(NCT00992589)
Timeframe: Baseline, Week 8

Interventionfrequency of Regurgitation (Mean)
Double-Blind Placebo-0.8
Double-Blind Rabeprazole Sodium 5 mg-0.8
Double-Blind Rabeprazole Sodium 10 mg-1.6
Double-Blind Rabeprazole Sodium Total-1.2

Change From Baseline in I-GERQ-R Total Score (Double-blind Phase/ Baseline Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Revised (I-GERQ-R) is a 12-item questionnaire that is completed by the primary caregiver at every office or telephonic visit. It has a weekly recall and the items cover the frequency, amount and discomfort attributed to spit-up, refusal or stopping feeding, crying and fussing, hiccups, arching back and stopping breathing or changing color. The total score is calculated as the sum of all 12 scores for the individual questions, and ranges from 0 to 42. A higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-3.6
Double-Blind Rabeprazole Sodium 5 mg-3.8
Double-Blind Rabeprazole Sodium 10 mg-4.1
Double-Blind Rabeprazole Sodium Total-3.9

Change From Baseline in in Weekly Average I-GERQ-DD Total Score (Double-blind Phase/ Baseline Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. Each of the 9 items will be assigned a numeric score. The total score will be calculated as the sum of all 9 items, and ranges from 0 to 37. A higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-1.9
Double-Blind Rabeprazole Sodium 5 mg-1.6
Double-Blind Rabeprazole Sodium 10 mg-2.1
Double-Blind Rabeprazole Sodium Total-1.9

Change From Baseline in Weekly Average I-GERQ-DD Discomfort Subscale Score (Double-blind Phase/ Last Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Discomfort subscale score will be calculated as the sum of the 3 questions regarding discomfort (Questions, 7, 8, 9) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo0.0
Double-Blind Rabeprazole Sodium 5 mg-0.1
Double-Blind Rabeprazole Sodium 10 mg-0.4
Double-Blind Rabeprazole Sodium Total-0.2

Change From Baseline in Weekly Average I-GERQ-DD Eating Behavior Subscale Score (Double-blind Phase/ Last Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Eating Behavior subscale score will be calculated as the sum of the 3 questions regarding eating behavior (Questions 4, 5, 6) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-0.1
Double-Blind Rabeprazole Sodium 5 mg-0.1
Double-Blind Rabeprazole Sodium 10 mg-0.4
Double-Blind Rabeprazole Sodium Total-0.3

Change From Baseline in Weekly Average I-GERQ-DD Regurgitation Subscale Score (Double-blind Phase/ Last Observation Carried Forward)

The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Regurgitation subscale will be calculated as the sum of the 3 questions regarding regurgitation (Questions 1, 2, 3) and will range from 0 to 13. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8

Interventionscores on a scale (Mean)
Double-Blind Placebo-0.8
Double-Blind Rabeprazole Sodium 5 mg-0.8
Double-Blind Rabeprazole Sodium 10 mg-1.0
Double-Blind Rabeprazole Sodium Total-0.9

Change From Baseline in Weight-for-Age Z-Score (Double-blind Phase/ Baseline Observation Carried Forward)

Body weight was measured with the participant unclothed and before a feeding during each office visit. In the analysis of weight data, weight will be transformed to the weight-for-age Z-score using World Health Organization Child Growth Standards, taking into account the infant's age and gender (Borghi E, 2006). (NCT00992589)
Timeframe: Baseline, Week 8

InterventionZ-score (Mean)
Double-Blind Placebo0.11
Double-Blind Rabeprazole Sodium 5 mg0.16
Double-Blind Rabeprazole Sodium 10 mg0.11
Double-Blind Rabeprazole Sodium Total0.14

The Daily Average Number of Episodes Related to Each Volume of Regurgitation During the Double-blind Treatment Period

(NCT00992589)
Timeframe: Baseline, Week 8

,,,,,,,
Interventionnumber of episodes (Mean)
Less than 1 tablespoon1 to 2 tablespoonsMore than 2 tablespoons to 2 fluid ozMore than 2 fluid oz to 4 fluid ozMore than 4 fluid oz
Double-Blind Placebo - Baseline1.20.70.30.10.0
Double-Blind Placebo - Week 80.80.50.20.00.0
Double-Blind Rabeprazole Sodium 10 mg - Baseline1.91.20.30.00.0
Double-Blind Rabeprazole Sodium 10 mg - Week 81.00.70.20.00.0
Double-Blind Rabeprazole Sodium 5 mg - Baseline1.10.70.20.00.0
Double-Blind Rabeprazole Sodium 5 mg - Week 80.70.40.10.00.0
Double-Blind Rabeprazole Sodium Total - Baseline1.51.00.20.00.0
Double-Blind Rabeprazole Sodium Total - Week 80.90.60.20.00.0

Trials

3 trials available for rabeprazole and Vomiting

ArticleYear
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:6

    Topics: Abdominal Pain; Body Weight; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Es

2013
Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
    Journal of pediatric gastroenterology and nutrition, 2014, Volume: 58, Issue:2

    Topics: Body Weight; Double-Blind Method; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Male; Pr

2014
Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
    Journal of pediatric gastroenterology and nutrition, 2014, Volume: 58, Issue:4

    Topics: Abdominal Pain; Child; Child, Preschool; Diarrhea; Double-Blind Method; Endoscopy, Gastrointestinal;

2014

Other Studies

1 other study available for rabeprazole and Vomiting

ArticleYear
Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus.
    The American journal of gastroenterology, 2015, Volume: 110, Issue:8

    Topics: Aged; Barrett Esophagus; Bilirubin; Deglutition Disorders; Esophageal pH Monitoring; Female; Gastroe

2015